



University City Science Center



## Request for Proposals (White Papers)

### Proof-of-Concept R&D Projects for Commercialization of Therapeutic, Diagnostic, or Life Science Research Tool Technologies

Opening Date: April 6, 2009

#### Background and Purpose:

The purpose of this broadly-scoped funding opportunity is to support proof-of-concept research projects related to life science technologies with high commercial potential in the healthcare industry. Such technologies may include, but are not limited to, therapeutic or preventative agents, medical devices, *in vitro* diagnostic tools, monitoring platforms, imaging agents, and research tools. Healthcare topic areas may include, but are not limited to, cancer, infectious diseases, neurodegenerative diseases, cardiovascular disease, musculoskeletal disorders, and pediatrics. Proof-of-concept research activities are defined as those that will answer critical “go/no-go” questions regarding the suitability of the technology for commercial development. Applications will be assessed by peer scientists, industry experts and life science investors. This funding opportunity is expected to support risk assessment of the technology in key areas that will facilitate follow-on development through a start-up company or licensing mechanism.

#### Budget, Project Period, and Scope:

For this opportunity, budgets up to \$200,000 in total costs, and project periods up to 12 months may be requested. Indirect costs (excluding fringe benefits) will be limited to a maximum of 5% of total costs. Projects may propose any relevant scope of research activities (including laboratory, pre-clinical, or clinical activities) that can be completed within the budget and time period limitations.

#### Eligible Institutions/Organizations:

Projects from the following organizations are eligible: Children’s Hospital of Philadelphia, Drexel University, Lankenau Institute for Medical Research, Rutgers University, Temple University, Thomas Jefferson University, University of Delaware, University of Pennsylvania, University of the Sciences in Philadelphia, and The Wistar Institute. Collaborative applications from multiple eligible institutions are encouraged, and will utilize sub-award budgets. Collaboration with other organizations is permitted, but the primary contract must be awarded directly to one of the listed eligible institutions. Employees of eligible organizations who demonstrate sufficient experience, knowledge, skills, and resources necessary to carry out the proposed research may submit applications.

#### Application Instructions and Materials:

White Paper application forms and instructions may be obtained from the QED website ([www.sciencecenter.org/qed-rfp](http://www.sciencecenter.org/qed-rfp)), where Investigators should also submit their White Papers electronically. Submitted White Papers will be automatically directed to your Technology Transfer Office (TTO) which will review and forward compliant applications to QED. **You should contact your TTO before beginning your application to check their final date for accepting White Papers.** Your TTO contact can be found in the “Instructions for Completing and Submitting QED White Papers” or on the QED website. Early submissions may receive the benefit of pre-submission feedback from the QED Program Director. White Papers will be evaluated by industry and investor experts. Successful applicants will be invited to submit a Full Application, in consultation with an assigned business/commercial advisor.

#### Key Dates for this Funding Cycle:

Opening date for White Papers: April 6, 2009

Last date for receipt of “Early Submissions” by QED: April 22, 2009 (consult your TTO for its deadline)

Closing date for QED receipt of White Papers: May 6, 2009 (consult your TTO for its deadline)

Invitation for Full Applications: (target date) May 22, 2009

Deadline for Full Applications: (target date) July 21, 2009

Funding decisions announced: (target date) September 1, 2009

Funding start date: (target date) September 15, 2009